9 reports

  • 8.1 References
  • UROLOGIC ONCOLOGY THERAPEUTICS MARKET, GLOBAL, FORECAST MARKET SHARE BY

Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics Summary Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer – the key indications covered...

  • Cancer
  • Therapy
  • Urology
  • Medivation, Inc.
  • Pfizer Inc.
  • 2. Global Prostate Cancer Therapeutics Market
  • 1. Executive Summary

Prostate Cancer remains a top priority for health systems around the world as incidence level rises, fueled by growing and aging populations. The main drivers for the prostate cancer market are the increase in the global aging population, innovation in drugs and developments in genomics and proteomics. The prostate cancer market faces some...

  • Cancer
  • Prostate Cancer
  • Therapy
  • Astellas Pharma Inc.
  • Medivation, Inc.
  • Pipeline: Triple-Negative Breast Cancer
  • PHASE III PIPELINE PRODUCTS IN DEVELOPMENT FOR TRIPLE-NEGATIVE BREAST CANCER

The aggressive nature of triple-negative breast cancer and a lack of targeted therapies creates opportunities for pipeline candidates to fulfil areas of high unmet need. This report addresses the following questions: - Which branded therapies will have the largest commercial potential in the triple-negative breast cancer...

  • Cancer
  • European Union
  • Japan
  • United States
  • Medivation, Inc.

Prostate cancer

4546 5000 3864
  • Pipeline: Prostate Cancer
  • Marketed Drugs: Prostate Cancer

The value of the prostate cancer market will more than double during 2015–24, reaching $13.5bn in 2024 at a compound annual growth rate (CAGR) of 8.6%. This report addresses the following questions: - Which products will drive the growth of the prostate cancer market during 2015–24? - Which geographic markets will experience...

  • Cancer
  • Prostate Cancer
  • Therapy
  • Market Size
  • Medivation, Inc.
  • 4.3 GLOBAL BREAST CANCER MARKET OPPORTUNITY
  • 7.4 MEDIVATION, INC.

Scope of the Report The report titled “Global PARP Inhibitor Market: Size, Trends and Forecasts (2016-2020)” provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza,...

  • Cancer
  • Targeted Therapy
  • Therapy
  • Market Size
  • Medivation, Inc.
  • cancer patients.
  • Opportunity - Prostate Cancer Market

Medivation Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This up-to-the-minute company report...

  • Cancer
  • United States
  • Company
  • Company Financials
  • Medivation, Inc.
  • FINANCIAL ADVISOR
  • PRODUCT DESCRIPTION

Summary Medivation Inc (Medivation), a subsidiary of Pfizer is a biopharmaceutical company which develops and commercializes medically innovative therapies to treat serious diseases.The company’s product Xtandi is developed for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). The...

  • Cancer
  • United States
  • World
  • Deals & Alliance
  • Medivation, Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2018
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.
  • Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development
  • Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Cancer
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.